Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch.

Medicina (Kaunas) · 2023 · PMC9964409 · PMID 36837465

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

slightly significantp = 0.049actually significant

The mean BCVA did not differ among study groups at any 3 month interval during the 24-month follow-up, except for at month 6, which showed slightly significant better mean BCVA in the AFB group (0.44 ± 0.34) in comparison to the RNB (0.5 ± 0.38) and RNB to AFB groups (0.5 ± 0.37) ( p = 0.049).

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.